Financial news, mergers and acquisitions, partnerships, and alliances.
NYU Winthrop has granted Progenity an exclusive license to patents that it holds covering a biomarker for predicting preterm births.
The deal covers the PlexBio IntelliPlex diagnostic instrument platform and reagent kits for oncology and infectious disease testing.
Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.
FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.
The firm is also developing a methylated DNA biomarker test — called EsoCheck Dx — for Barrett's esophagus that uses samples collected with EsoCheck.